Myeloid bodies is not an uncommon ultrastructural finding

References

• Jao W, Manaligod JR, Gerardo LT, Castillo MM. Myeloid bodies in drug-induced acute tubular necrosis. J Pathol. 1983;139(1):33–40. doi:https://doi.org/10.1002/path.1711390104.
   PubMed Web of Science ®Google Scholar
• Bracamonte ER, Kowalewska J, Starr J, Gitomer J, Alpers CE. Iatrogenic phospholipidosis mimicking Fabry disease. Am J Kidney Dis. 2006;48(5):844–850. doi:https://doi.org/10.1053/j.ajkd.2006.05.034.
   PubMed Web of Science ®Google Scholar
• Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43(5):1003–1012. doi:https://doi.org/10.1128/AAC.43.5.1003.
   PubMed Web of Science ®Google Scholar
• de Menezes Neves PDM, Machado JR, Custódio FB, et al. Ultrastructural deposits appearing as “zebra bodies” in renal biopsy: Fabry disease?- comparative case reports. BMC Nephrol. 2017;18(1):157. doi:https://doi.org/10.1186/s12882-017-0571-0.
   PubMed Web of Science ®Google Scholar
• Cornell LD, Leung N. Myeloid bodies in acute tubular injury. Kidney Int. 2021;99(4):1027. doi:https://doi.org/10.1016/j.kint.2020.08.018.
   PubMed Web of Science ®Google Scholar
• Costa RM, Martul EV, Reboredo JM, Cigarrán S. Curvilinear bodies in hydroxychloroquine-induced renal phospholipidosis resembling Fabry disease. Clin Kidney J. 2013;6(5):533–536.doi:https://doi.org/10.1093/ckj/sft089.
   PubMedGoogle Scholar
• Bojic M, Kozakowski N, Becede M, Kerschbaumer A, Bobacz K. The Case | myeloid bodies in the kidney biopsy of a patient with systemic lupus erythematosus. Kidney Int. 2017;92(1):271–272. doi:https://doi.org/10.1016/j.kint.2016.12.025.
   PubMed Web of Science ®Google Scholar
• Mehta A, Beck M, Linhart A, Sunder-Plassmann G, Widmer U. History of lysosomal storage diseases: an overview. Mehta A, Beck M, and Sunder-Plassmann G . eds. Fabry Disease: Perspectives from 5 Years of FOS.Oxford: Oxford PharmaGenesis, Chapter 1. 2006.
   Google Scholar
• Hashimoto K, Gross BG, Lever WF. Angiokeratoma corporis diffusum (Fabry). Histochemical and electron microscopic studies of the skin. J Invest Dermatol. 1965;44(2):119–128. doi:https://doi.org/10.1038/jid.1965.22.
   PubMed Web of Science ®Google Scholar
• Nelson AA, Fitzhugh OG. Chloroquine (SN-7618) pathologic changes observed in rats which for 2 years had been fed various proportions. Arch Pathol (Chic). 1948;45(4):454–462.
   PubMedGoogle Scholar
• Kosek JC, Mazze RI, Cousins MJ. Nephrotoxicity of gentamicin. Lab Invest. 1974;30:48–57.
   PubMed Web of Science ®Google Scholar
• Houghton DC, Campbell-Boswell MV, Bennett WM, Porter GA, Brooks RE. Myeloid bodies in the renal tubules of humans: relationship to gentamicin therapy. Clin Nephrol. 1978;10:140–145.
   PubMed Web of Science ®Google Scholar
• Gray JE, Purmalis A, Purmalis B, Mathews J. Ultrastructural studies of the hepatic changes brought about by Clindamycin and Erythromycin in animals. Toxicol Appl Pharmacol. 1971;19(2):217–233. doi:https://doi.org/10.1016/0041-008X(71)90108-6.
   PubMed Web of Science ®Google Scholar
• Reasor MJ, Hastings KL, Ulrich RG. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf. 2006;5(4):567–583. doi:https://doi.org/10.1517/14740338.5.4.567.
   PubMed Web of Science ®Google Scholar
• Pintavorn P, Cook WJ. Progressive renal insufficiency associated with amiodarone-induced phospholipidosis. Kidney Int. 2008;74(10):1354–1357. doi:https://doi.org/10.1038/ki.2008.229.
   PubMed Web of Science ®Google Scholar
• De Broe ME, Paulus GJ, Verpooten GA, et al. Early effects of gentamicin, tobramycin, and amikacin on the human kidney. Kidney Int. 1984;25(4):643–652. doi:https://doi.org/10.1038/ki.1984.69.
   PubMed Web of Science ®Google Scholar
• Spaet RH, Sullivan DJ, Diener RM. Occurrence of myeloid bodies in rats following two-year administration of imipramine hydrochloride. Toxicol Pathol. 1983;11(1):3–11. doi:https://doi.org/10.1177/019262338301100102.
   PubMedGoogle Scholar
• Naseer MS, Chand R, Coppola S, Abreo A, Sharma M, Singh N. Post-transplant de-novo renal phospholipidosis in a kidney transplant recipient: Fabry disease or something else? Clin Nephrol Case Stud. 2020;8(1):46–48. doi:https://doi.org/10.5414/CNCS110131.
   PubMedGoogle Scholar
• Hanumegowda UM, Wenke G, Regueiro-Ren A, Yordanova R, Corradi JP, Adams SP. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. Chem Res Toxicol. 2010;23(4):749–755. doi:https://doi.org/10.1021/tx9003825.
   PubMed Web of Science ®Google Scholar
• Lantuejoul S, Brambilla E, Brambilla C, Devouassoux G. Statin-induced fibrotic nonspecific interstitial pneumonia. Eur Respir J. 2002;19(3):577–580. doi:https://doi.org/10.1183/09031936.02.00258802.
   PubMed Web of Science ®Google Scholar
• Fischer H, Atzpodien EA, Csato M, et al. In silico assay for assessing phospholipidosis potential of small drug like molecules: training, validation, and refinement using several data sets. J Med Chem. 2012;55(1):126–139. doi:https://doi.org/10.1021/jm201082a.
   PubMed Web of Science ®Google Scholar
• Sawada H, Takami K, Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005;83(2):282–292. doi:https://doi.org/10.1093/toxsci/kfh264.
   PubMed Web of Science ®Google Scholar
• Huang LK, Tsai MJ, Tsai HC, Chao HS, Lin FC, Chang SC. Statin-induced lung injury: diagnostic clue and outcome. Postgrad Med J. 2013;89(1047):14–19. doi:https://doi.org/10.1136/postgradmedj-2011-130209.
   PubMed Web of Science ®Google Scholar
• Rainey MM, Korostyshevsky D, Lee S, Perlstein EO. The antidepressant sertraline targets intracellular vesiculogenic membranes in yeast. Genetics. 2010;185(4):1221–1233. doi:https://doi.org/10.1534/genetics.110.117846.
   PubMed Web of Science ®Google Scholar
• Shahane SA, Huang R, Gerhold D, Baxa U, Austin CP, Xia M. Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format. J Biomol Screen. 2014;19(1):66–76.
   PubMedGoogle Scholar
• Ferslew BC, Brouwer KL. Identification of hepatic phospholipidosis inducers in sandwich-cultured rat hepatocytes, a physiologically relevant model, reveals altered basolateral uptake and biliary excretion of anionic probe substrates. Toxicol Sci. 2014;139(1):99–107. doi:https://doi.org/10.1093/toxsci/kfu033.
   PubMed Web of Science ®Google Scholar
• Vitovic P, Alakoskela JM, Kinnunen PK. Assessment of drug-lipid complex formation by a high-throughput Langmuir-balance and correlation to phospholipidosis. J Med Chem. 2008;51(6):1842–1848. doi:https://doi.org/10.1021/jm7013953.
   PubMed Web of Science ®Google Scholar
• Joshi UM, Rao P, Kodavanti S, Lockard VG, Mehendale HM. Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: relevance to phospholipidosis. Biochim Biophys Acta. 1989;1004(3):309–320. doi:https://doi.org/10.1016/0005-2760(89)90078-7.
   PubMed Web of Science ®Google Scholar
• Van Bambeke F, Montenez JP, Piret J, Tulkens PM, Courtoy PJ, Mingeot-Leclercq MP. Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. Eur J Pharmacol. 1996;314(1–2):203–214. doi:https://doi.org/10.1016/S0014-2999(96)00552-3.
   PubMed Web of Science ®Google Scholar
• Hinkovska-Galcheva V, Treadwell T, Shillingford JM, et al. Inhibition of lysosomal phospholipase A2 predicts drug-induced phospholipidosis. J Lipid Res. 2021;62:100089. doi:https://doi.org/10.1016/j.jlr.2021.100089.
   PubMed Web of Science ®Google Scholar
• Mingeot-Leclercq MP, Brasseur R, Schanck A. Molecular parameters involved in aminoglycoside nephrotoxicity. J Toxicol Environ Health. 1995;44(3):263–300. doi:https://doi.org/10.1080/15287399509531960.
   PubMed Web of Science ®Google Scholar
• Hurwitz R, Ferlinz K, Sandhoff K. The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem Hoppe Seyler. 1994;375(7):447–450.doi:https://doi.org/10.1515/bchm3.1994.375.7.447.
   PubMed Web of Science ®Google Scholar
• Nord JE, Shah PK, Rinaldi RZ, Weisman MH. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum. 2004;33(5):336–351. doi:https://doi.org/10.1016/j.semarthrit.2003.09.012.
   PubMed Web of Science ®Google Scholar
• Shayman JA, Abe A. Drug induced phospholipidosis: an acquired lysosomal storage disorder. Biochim Biophys Acta. 2013;1831(3):602–611. doi:https://doi.org/10.1016/j.bbalip.2012.08.013.
   PubMed Web of Science ®Google Scholar
• Liu FL, Cohen RD, Downar E, Butany JW, Edelson JD, Rebuck AS. Amiodarone pulmonary toxicity: functional and ultrastructural evaluation. Thorax. 1986;41(2):100–105. doi:https://doi.org/10.1136/thx.41.2.100.
   PubMed Web of Science ®Google Scholar
• Muller-Hocker J, Schmid H, Weiss M, Dendorfer U, Braun GS. Chloroquine-induced phospholipidosis of the kidney mimicking Fabry’s disease: case report and review of the literature. Hum Pathol. 2003;34(3):285–289. doi:https://doi.org/10.1053/hupa.2003.36.
   PubMed Web of Science ®Google Scholar
• Albay D, Adler SG, Philipose J, Calescibetta CC, Romansky SG, Cohen AH. Chloroquine-induced lipidosis mimicking Fabry disease. Mod Pathol. 2005;18(5):733–738. doi:https://doi.org/10.1038/modpathol.3800344.
   PubMed Web of Science ®Google Scholar
• Chew E, Ghosh M, McCulloch C. Amiodarone-induced cornea verticillata. Can J Ophthalmol. 1982;17:96–99.
   PubMed Web of Science ®Google Scholar
• Reasor MJ, Kacew S. Drug-induced phospholipidosis: are there functional consequences? Exp Biol Med (Maywood). 2001;226(9):825–830.doi:https://doi.org/10.1177/153537020122600903.
   PubMed Web of Science ®Google Scholar
• Reasor MJ, Ogle CL, Kacew S. Amiodarone-induced pulmonary toxicity in rats: biochemical and pharmacological characteristics. Toxicol Appl Pharmacol. 1989;97(1):124–133. doi:https://doi.org/10.1016/0041-008X(89)90061-6.
   PubMed Web of Science ®Google Scholar
• Wilson BD, Clarkson CE, Lippmann ML. Amiodarone-induced pulmonary inflammation. Correlation with drug dose and lung levels of drug, metabolite, and phospholipid. Am Rev Respir Dis. 1991;143(5 Pt 1):1110–1114. doi:https://doi.org/10.1164/ajrccm/143.5_Pt_1.1110.
   PubMed Web of Science ®Google Scholar
• Su H, Ye C, Wen Q, Zhu HY, Yi LX, Zhang C. Case report: lipid inclusion in glomerular endothelial and mesangial cells in a patient after contrast medium injection. BMC Nephrol. 2018;19(1):53. doi:https://doi.org/10.1186/s12882-018-0844-2.
   PubMed Web of Science ®Google Scholar
• Banks DE, Milutinovic J, Desnick RJ, Grabowski GA, Lapp NL, Boehlecke BA. Silicon nephropathy mimicking Fabry’s disease. Am J Nephrol. 1983;3(5):279–284. doi:https://doi.org/10.1159/000166730.
   PubMed Web of Science ®Google Scholar
• Lei L, Oh G, Sutherland S, et al. Myelin bodies in LMX1B-associated nephropathy: potential for misdiagnosis. Pediatr Nephrol. 2020;35(9):1647–1657. doi:https://doi.org/10.1007/s00467-020-04564-w.
   PubMed Web of Science ®Google Scholar
• Pinto EVF, Pichurin PN, Fervenza FC, et al. Nail-patella-like renal disease masquerading as Fabry disease on kidney biopsy: a case report. BMC Nephrol. 2020;21(1):341. doi:https://doi.org/10.1186/s12882-020-02012-3.
   PubMed Web of Science ®Google Scholar
• Grafft CA, Fervenza FC, Semret MH, Orloff S, Sethi S. Renal involvement in Niemann-Pick Disease. NDT Plus. 2009;2(6):448–451.doi:https://doi.org/10.1093/ndtplus/sfp101.
   PubMedGoogle Scholar
• Meehan SM, Junsanto T, Rydel JJ, Desnick RJ. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications. Am J Kidney Dis. 2004;43(1):164–171. doi:https://doi.org/10.1053/j.ajkd.2003.09.022.
   PubMed Web of Science ®Google Scholar
• Von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med. 1991;324(6):395–399. doi:https://doi.org/10.1056/NEJM199102073240607.
   PubMed Web of Science ®Google Scholar
• Sakuraba H, Oshima A, Fukuhara Y, et al. Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet. 1990;47(5):784–789.
   PubMed Web of Science ®Google Scholar
• Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64(3):801–807. doi:https://doi.org/10.1046/j.1523-1755.2003.00160.x.
   PubMed Web of Science ®Google Scholar
• Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236–242. doi:https://doi.org/10.1111/j.1365-2362.2004.01309.x.
   PubMed Web of Science ®Google Scholar
• Hanaoka H, Hashiguchi A, Konishi K, Ishii T, Kuwana M. A rare association between Fabry’s disease and granulomatosis with polyangiitis: a potential pathogenic link. BMC Nephrol. 2014;15(1):157. doi:https://doi.org/10.1186/1471-2369-15-157.
   PubMed Web of Science ®Google Scholar
• Ren H, Li L, Yu J, et al. Fabry disease and immunoglobulin A nephropathy presenting with Alport syndrome-like findings: a case report. Medicine (Baltimore). 2019;98(28):e16256. doi:https://doi.org/10.1097/MD.0000000000016256.
   PubMed Web of Science ®Google Scholar
• Chao CT, Lin WC, Kao TW. Fabry disease and immunoglobulin A nephropathy. Nephrology (Carlton). 2012;17(8):782–783. doi:https://doi.org/10.1111/j.1440-1797.2012.01594.x.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xie H, Lin HL, et al. Coexistence of Fabry disease and membranous nephropathy. Iran J Kidney Dis. 2016;10(1):48–50.
   PubMed Web of Science ®Google Scholar
• Breiden B, Sandhoff K. Emerging mechanisms of drug-induced phospholipidosis. Biol Chem. 2019;401(1):31–46. doi:https://doi.org/10.1515/hsz-2019-0270.
   PubMed Web of Science ®Google Scholar